Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities

• DOI: 10.1073/pnas.1611421113
• Publication Date: 2016-10-04T03:18:46Z
• Authors: Sumit K. Subudhi; Ana Aparicio; Jianjun Gao; Amado J. Zurita; John C. Araujo; Christopher J. Lo...; Salahaldin A. Tahir; Brinda R. Korivi; Rebecca S. Slack; Luis Vence; Ryan O. Emerson; Erik Yusko; Marissa Vignali; Harlan S. Robins; Jingjing Sun; James P. Allison; Padmanee Sharma
• Keywords: Immune checkpoint

Significance Immune checkpoint therapies have garnered significant attention due to their ability induce dramatic clinical responses in patients with various solid tumor malignancies, including prostate cancer. However, these therapeutic agents often elicit immune-related adverse events (irAEs) that may result substantial morbidity. Early intervention can markedly reduce the severity of irAEs, but biomarkers allow for early detection and guide management are lacking. Based on peripheral blood samples collected longitudinally two cancer trials, we propose CD8 T-cell clonal expansion within systemic circulation as a potential correlative biomarker occur ipilimumab therapy.